Policy #	Policy Name	Brief Description of Policy Change	Reason for Changes
NEW	Iwilfin(eflornithine)	On December 13, 2023, the Food and Drug Administration approved eflornithine (IWILFIN, USWM, LLC) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.	New FDA Drug/ Indication
UM ONC_1042	Somatostatin Analog: Sandostatin (octreotide) and Somatuline	Annual Review	
UM ONC_1195	Votrient (pazopanib)	Annual Review	
UM ONC_1260	Beleodaq (belinosat)	Annual Review	
UM ONC_1282	Imlygic (Talimogene Laherparepvec)	Annual Review	
UM ONC_1361	Erwinaze (asparaginase Erwinia chrysanthemi)	Annual Review	
UM ONC_1414	Gavreto (pralsetinib)	Annual Review	
UM ONC_1459	Kimmtrak (tebentafusp-tebn)	Annual Review	
UM ONC_1468	Antiemetics	Annual Review	
UM ONC_1471	Elahere (mirvetuximab soravtansine-gynx)	Annual Review	